{"id":3259,"date":"2024-06-10T11:22:38","date_gmt":"2024-06-10T15:22:38","guid":{"rendered":"https:\/\/cytel.agencyukdev.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/"},"modified":"2024-08-22T06:09:24","modified_gmt":"2024-08-22T10:09:24","slug":"raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i","status":"publish","type":"perspectives","link":"https:\/\/cytel.agencyukdev.com\/fr\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/","title":{"rendered":"Raising the Awareness for Additional FDA Data Submission Recommendations (Part I)"},"content":{"rendered":"

For years CDISC data standards implementers have struggled to find good implementation examples and use cases beside those provided in the CDISC Implementation Guidance (IG). However, in the recent years, thanks to the efforts of several different experts, such as clinicians in the different Therapeutic Areas or data standards experts, several CDISC Therapeutic Area User Guidance (TAUG) have been made available [1, 2, 3]<\/sup>. As I write this blog, 46 TAUGs are available from various therapeutic areas, such as Oncology, Neurology, Endocrinology, Cardiovascular, Infective Diseases, Autoimmune Diseases, Mental Health, Gastrointestinal, and others. The use of and adherence to many of these TAUGs is recommended by the FDA in its Study Data Technical Conformance Guidance (SDTCG) [4]<\/sup>, and as per the March-2022 version, 24 TAUGs are \u201csupported\u201d.<\/p>\n

Moreover, regulatory agencies such as the FDA have also released some additional guidances either specific to an FDA division or covering any specific medical aspects, with the aim of reducing the variability in interpretation of CDISC IG. In a previous blog , I discussed the detailed ADaM specifications provided by the FDA Office of Oncologic Diseases in support of Real Time Oncology Review [5]<\/sup>.<\/p>\n

<\/p>\n

Despite the following statement in most if not all FDA guidances, the FDA divisions expect that these recommendations are followed, and this is also confirmed by some comments we received during certain pre-NDA and pre-BLA meetings:<\/p>\n

\u201cIn general, FDA\u2019s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency\u2019s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required\u201d<\/p>\n

Ironically, the \u201cabundance\u201d of guidances and agency recommendations, aka \u201crequirements\u201d, has complicated the work of data standards implementers, as also discussed by the Pfizer programming team at PHUSE-US 2020 [6]. This is even more true in the CRO world where \u201cspecialization\u201d is less common than on the Sponsor side where data standards implementers can focus on few therapeutic areas, often one, thus becoming experts on those therapeutic areas. Recently, during a bid defense meeting a sponsor asked us if our programming team has been \u201ceducated\u201d on an FDA guidance specific to Vaccines [7] data submission; obviously, with more than 300 programmers, biostatisticians, and data managers, it is challenging to accomplish such a requirement and expect that all our employees are familiar with the content of more than fifty documents.<\/p>\n

The only possible approach is “raising the awareness\u201d which means having a data standards governance team in place, like the one we have at Cytel, that is responsible for regularly assessing new guidance, \u201cdigesting\u201d and making them available to the rest of the team, and ensuring that everyone who is dealing with data standards is aware that some specific requirements may be available in the therapeutic area or specific indications that they are working on.<\/p>\n

All these guidances are referenced in the FDA SDTCG in section
\n\u201c5. List of FDA Technical Specification Documents,\u201d on the Study Data Standards Resources FDA webpage in section \u201c3. Technical Guidance,\u201d [8] and listed in the following table:<\/p>\n

 <\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
#<\/strong><\/td>\nFDA Additional Data Standards Guidance References<\/strong><\/td>\n<\/tr>\n
1<\/td>\nVaccines<\/strong> Technical Specification Guidance v2.1 (December 2019)
\nhttps:\/\/www.fda.gov\/media\/112581\/download<\/a><\/td>\n<\/tr>\n
2<\/td>\nQT Studies<\/strong> Technical Specification Document v1.0 (June 2019)
\nhttps:\/\/www.fda.gov\/media\/128187\/download<\/a><\/td>\n<\/tr>\n
3<\/td>\nSubmitting Select Clinical Trial Data Sets for Drugs Intended to Treat Human Immunodeficiency Virus-1 Infection<\/strong> (March 2018)
\nhttps:\/\/www.fda.gov\/media\/112667\/download<\/a><\/td>\n<\/tr>\n
4<\/td>\nTechnical Specifications\u2014Comparative Clinical Endpoint Bioequivalence Study Analysis Datasets<\/strong> for Abbreviated New Drug Applications (September 2018)
\nhttps:\/\/www.fda.gov\/media\/116187\/download<\/a><\/td>\n<\/tr>\n
5<\/td>\nTechnical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH)<\/strong> (January 2022) [9]<\/sup>
\nhttps:\/\/www.fda.gov\/media\/151864\/download<\/a><\/td>\n<\/tr>\n
6<\/td>\nSubmitting Next Generation Sequencing Data to the Division of Antiviral Products<\/strong> v1.0 (July 2019)
\nhttps:\/\/www.fda.gov\/media\/129126\/download<\/a><\/td>\n<\/tr>\n
7<\/td>\nData Standards for Drug and Biological Product Submissions Containing Real-World Data<\/strong> (October 2021) \u2013 Draft
\nhttps:\/\/www.fda.gov\/media\/153341\/download<\/a><\/td>\n<\/tr>\n
8<\/td>\nSubmitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies<\/span> of Pharmaceuticals (May 2021)
\nhttps:\/\/www.fda.gov\/media\/149870\/download<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

 <\/p>\n

In Part II of this blog, I will try to provide more details on key topics covered by each of these guidances and share the experience, like the one Pfizer presenters shared at PHUSE US Connect 2020 [6]<\/sup>, we had with the FDA agencies commenting on our data packages by referencing to some of these FDA guidances. Stay tuned!<\/p>\n

Part II now available! Click here<\/a> to read this important update.<\/span><\/strong><\/p>\n

 <\/p>\n

References:<\/span><\/strong><\/p>\n

[1] \u201cCDISC Therapeutic Areas”<\/span>\u00a0https:\/\/www.cdisc.org\/standards\/therapeutic-areas<\/a><\/span><\/p>\n

[2]<\/span> <\/span>\u201cTherapeutic Area User Guidance \u2013 The Hidden Gems\u201c (Cytel Blog, July 2020) https:\/\/cytel.agencyukdev.com\/blog\/therapeutic-area-user-guidance-the-hidden-gems<\/a><\/p>\n

[3] A Systematic Review of CDISC TAUGs\u201d, A. Tinazzi, PharmaSUG-China, 2019, Shanghai https:\/\/www.pharmasug.org\/proceedings\/china2019\/DS\/Pharmasug-China-2019-DS69.pdf<\/a><\/p>\n

[4] \u201cFDA Study Data Technical Conformance Guidance \u00bb (March 2022) https:\/\/www.fda.gov\/media\/153632\/download<\/a><\/p>\n

[5] \u201cThe FDA Real-Time Oncology Review Process: An opportunity & Challenge for Sponsors \u00bb (Cytel Blog November 2021) https:\/\/cytel.agencyukdev.com\/blog\/the-fda-real-time-oncology-review-process-an-opportunity-challenge-for-sponsors<\/a><\/p>\n

[6] \u201cChallenges with Implementation of New Standards and Guidance \u2013 A Sponsor\u2019s Experience with the April 2018 CBER Vaccine Guidance\u201d, S. VanPelt Nguyen and L. Zhang, PHUSE US Connect 2020 https:\/\/www.lexjansen.com\/phuse-us\/2020\/ds\/DS05.pdf<\/a><\/p>\n

[7] \u201cVaccines Technical Specification Guidance\u201c v2.1 (December 2019) https:\/\/www.fda.gov\/media\/112581\/download<\/a><\/p>\n

[8] \u201cFDA Study Data Standards Resources\u201d https:\/\/www.fda.gov\/industry\/fda-data-standards-advisory-board\/study-data-standards-resources<\/a><\/p>\n

[9] \u201cImpact of FDA Technical Specifications on CDISC Implementation for NASH Trials\u201d, C\u00e9cile Cornou; Henning Pontoppidan, Novo Nordisk A\/S CDISC EU Interchange 2022<\/p>\n

 <\/p>\n","protected":false},"featured_media":3105,"parent":0,"template":"","meta":{"_acf_changed":false},"tags":[76],"by-topic":[414],"by-year":[72],"class_list":["post-3259","perspectives","type-perspectives","status-publish","has-post-thumbnail","hentry","tag-blog","by-topic-cdisc","by-year-72"],"acf":[],"yoast_head":"\nRaising the Awareness for Additional FDA Data Submission Recommendations (Part I) - Clinical Trial Software & Data Analysis | Cytel | Contact Us<\/title>\n<meta name=\"description\" content=\"Cytel's clinical data submission expert, Angelo Tinazzi shares his insights on the additional FDA data standards submission recommendations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Raising the Awareness for Additional FDA Data Submission Recommendations (Part I) - Clinical Trial Software & Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"og:description\" content=\"Cytel's clinical data submission expert, Angelo Tinazzi shares his insights on the additional FDA data standards submission recommendations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Trial Software & Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-22T10:09:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/06\/Cytel_Abstract_1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\\\/\",\"url\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\\\/\",\"name\":\"Raising the Awareness for Additional FDA Data Submission Recommendations (Part I) - Clinical Trial Software & Data Analysis | Cytel | Contact Us\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Cytel_Abstract_1.jpg\",\"datePublished\":\"2024-06-10T15:22:38+00:00\",\"dateModified\":\"2024-08-22T10:09:24+00:00\",\"description\":\"Cytel's clinical data submission expert, Angelo Tinazzi shares his insights on the additional FDA data standards submission recommendations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Cytel_Abstract_1.jpg\",\"contentUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Cytel_Abstract_1.jpg\",\"width\":1920,\"height\":1280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Raising the Awareness for Additional FDA Data Submission Recommendations (Part I)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\",\"name\":\"Clinical Trial Software & Data Analysis | Cytel | Contact Us\",\"description\":\"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Raising the Awareness for Additional FDA Data Submission Recommendations (Part I) - Clinical Trial Software & Data Analysis | Cytel | Contact Us","description":"Cytel's clinical data submission expert, Angelo Tinazzi shares his insights on the additional FDA data standards submission recommendations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/","og_locale":"fr_FR","og_type":"article","og_title":"Raising the Awareness for Additional FDA Data Submission Recommendations (Part I) - Clinical Trial Software & Data Analysis | Cytel | Contact Us","og_description":"Cytel's clinical data submission expert, Angelo Tinazzi shares his insights on the additional FDA data standards submission recommendations.","og_url":"https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/","og_site_name":"Clinical Trial Software & Data Analysis | Cytel | Contact Us","article_modified_time":"2024-08-22T10:09:24+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/06\/Cytel_Abstract_1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/","url":"https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/","name":"Raising the Awareness for Additional FDA Data Submission Recommendations (Part I) - Clinical Trial Software & Data Analysis | Cytel | Contact Us","isPartOf":{"@id":"https:\/\/cytel.agencyukdev.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/#primaryimage"},"image":{"@id":"https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/#primaryimage"},"thumbnailUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Cytel_Abstract_1.jpg","datePublished":"2024-06-10T15:22:38+00:00","dateModified":"2024-08-22T10:09:24+00:00","description":"Cytel's clinical data submission expert, Angelo Tinazzi shares his insights on the additional FDA data standards submission recommendations.","breadcrumb":{"@id":"https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/#primaryimage","url":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Cytel_Abstract_1.jpg","contentUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Cytel_Abstract_1.jpg","width":1920,"height":1280},{"@type":"BreadcrumbList","@id":"https:\/\/www.cytel.com\/perspectives\/raising-the-awareness-for-additional-fda-data-submission-recommendations-part-i\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cytel.agencyukdev.com\/"},{"@type":"ListItem","position":2,"name":"Raising the Awareness for Additional FDA Data Submission Recommendations (Part I)"}]},{"@type":"WebSite","@id":"https:\/\/cytel.agencyukdev.com\/#website","url":"https:\/\/cytel.agencyukdev.com\/","name":"Clinical Trial Software & Data Analysis | Cytel | Contact Us","description":"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cytel.agencyukdev.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives\/3259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives"}],"about":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/types\/perspectives"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media\/3105"}],"wp:attachment":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media?parent=3259"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/tags?post=3259"},{"taxonomy":"by-topic","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-topic?post=3259"},{"taxonomy":"by-year","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-year?post=3259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}